Immuron Limited (ASX:IMC)
Australia · Delayed Price · Currency is AUD 0.0480
+0.0020 (4.35%)
Sep 18, 2026, 2:36 PM AEST
Immuron Revenue
In the fiscal year ending June 30, 2026, Immuron had annual revenue of 7.71M AUD with 5.85% growth. Immuron had revenue of 3.53M in the half year ending June 30, 2026, with 38.55% growth.
Revenue
7.71M
Revenue Growth
+5.85%
P/S Ratio
1.93
Revenue / Employee
1.10M
Employees
7
Market Cap
14.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 7.71M | 426.60K | 5.85% |
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.85M | -95.13% |
| Jun 30, 2020 | 2.99M | 604.81K | 25.33% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Argenica Therapeutics | 5.48M |
| Neurotech International | 4.73M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
| ReNerve | 510.36K |
| AdAlta | 404.25K |
Immuron News
- 13 days ago - Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up - Nasdaq
- 13 days ago - Immuron to launch Proibs in the U.S. - TheFly
- 13 days ago - Immuron to launch PROIBS® in the United States - GlobeNewsWire
- 20 days ago - Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges - Nasdaq
- 2 months ago - Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - GlobeNewsWire
- 2 months ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 4 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 5 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire